Recent Updates
Recently added Catalysts
OVID Positive Sentiment

AstraZeneca

Friday, September 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ovid has entered into an exclusive license agreement with AstraZeneca, acquiring worldwide rights to a portfolio of early-stage small molecule compounds that target the KCC2 transporter. This includes Ovid's lead compound, OV350, which is intended for all human therapeutic uses. Ovid will be responsible for the development and commercialization of these compounds.
Price reaction · baseline $3.51 (2023-09-22T16:05:00.000Z) · hit during market hours · 30 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+3.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Exclusive license agreement with AstraZeneca enhances Ovid's portfolio.
  • Worldwide rights to early-stage compounds targeting KCC2 transporter.
  • Ovid's lead compound OV350 has potential for various human therapeutic uses.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

On December 30, 2021, we entered into an exclusive license agreement with AstraZeneca. Under the terms of the AstraZeneca license agreement, we have obtained worldwide rights to a portfolio of early-stage, small molecule compounds targeting the KCC2 transporter, including our lead compound, OV350 for all human therapeutic uses. Ovid is responsible for using commercially reasonable efforts to carry out all future development and commercialization of KCC2 transporter activators.
Read Ovid press release »

Frequently Asked Questions

What agreement did Ovid enter with AstraZeneca?

Ovid entered into an exclusive license agreement with AstraZeneca.

What rights did Ovid obtain from AstraZeneca?

Ovid obtained worldwide rights to early-stage compounds targeting the KCC2 transporter.

What is Ovid's lead compound?

Ovid's lead compound is OV350, intended for all human therapeutic uses.

Who is responsible for the development of KCC2 activators?

Ovid is responsible for the development and commercialization of KCC2 transporter activators.

ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare Ovid AstraZeneca KCC2 transporter OV350 therapeutic uses
Last updated: Sep 22, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →